Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT

Inclusion Criteria: * Male or female participants aged 18 to 75 years. * Ability to understand the study and provide written informed consent before enrollment. * Receiving a stable lipid-lowering regimen before enrollment, with the type and dose of statin therapy remaining unchanged for at least 4 weeks. * Fasting triglyceride level below 5.6 mmol/L. * Presence of at least one of the following high-risk plaque features on coronary computed tomography angiography (CCTA):Pericoronary fat attenuation index greater than -70.1 Hounsfield units; * Low-attenuation plaque below 30 Hounsfield units; * Positive remodeling index greater than 1.1; * Spotty calcification; * or Napkin-ring sign, defined as a low-attenuation plaque core surrounded by a rim of higher attenuation. Exclusion Criteria: * Current participation in another investigational drug, device, or procedure study, or receipt of an investigational drug or device within 4 weeks before enrollment. * Treatment with icosapent ethyl within 12 months before enrollment. * Known intolerance or hypersensitivity to icosapent ethyl or fish oil. * A previous diagnosis of homozygous familial hypercholesterolemia or hyperlipidemia requiring hemodialysis. * Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, or stroke within 3 months before enrollment; * Planned cardiac surgery, percutaneous coronary intervention, or carotid artery stenting, or planned major noncardiac surgery d…